
We Claim

1. A compound of Formula **I**:



I,

or a pharmaceutically acceptable salt thereof, wherein:

R^1 is -$C_{(1-6)}$alkyl or -$C_{(0-3)}$alkyl$C_{(3-6)}$cycloalkyl;

wherein the -$C_{(1-6)}$alkyl and the -$C_{(0-3)}$alkyl$C_{(3-6)}$cycloalkyl are unsubstituted or substituted with one to six fluorine atoms;

R^2 is -$C_{(3-5)}$cycloalkyl;

R^3 is -$C_{(0-1)}$alkyl$C_{(3-6)}$cycloalkyl, wherein the -$C_{(0-1)}$alkyl$C_{(3-6)}$cycloalkyl is unsubstituted or substituted with one to five fluorine atoms;

R^4 is -$C_{(3-4)}$cycloalkyl or a 5- to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S;

wherein the $C_{(3-4)}$cycloalkyl is unsubstituted or substituted with one to three R^{4a} groups; and

wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or two R^{4b} groups;


each R^{4a} group is independently selected from -$C_{(1-4)}$alkyl that is unsubstituted or substituted with one to six fluorine atoms; and

each R^{4b} group is independently selected from -$C_{(0-2)}$alkyl$C_{(3-4)}$cycloalkyl or -$C_{(1-5)}$alkyl, wherein the -$C_{(0-2)}$alkyl$C_{(3-4)}$cycloalkyl and -$C_{(1-5)}$alkyl are unsubstituted or substituted with one to six fluorine atoms;

R^5 is H or F;

wherein

when R^4 is -$C_{(3-4)}$cycloalkyl then the compound of Formula **I** is a compound of Formula **Ia**:



Ia

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is -$C_{(1-6)}$alkyl or -$C_{(0-3)}$alkyl$C_{(3-6)}$cycloalkyl;

wherein the -$C_{(1-6)}$alkyl and the -$C_{(0-3)}$alkyl$C_{(3-6)}$cycloalkyl are unsubstituted or substituted with one to six fluorine atoms;

R^2 is -$C_{(3-5)}$cycloalkyl;

R^3 is -$C_{(0-1)}$alkyl$C_{(3-6)}$cycloalkyl, wherein the -$C_{(0-1)}$alkyl$C_{(3-6)}$cycloalkyl is unsubstituted or substituted with one to five fluorine atoms;

R^4 is a 5- to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N, O, and S;

wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or two R^{4b} groups;

each R^{4b} group is independently selected from -$C_{(0-2)}$alkyl$C_{(3-4)}$cycloalkyl or -$C_{(1-5)}$alkyl, wherein the -$C_{(0-2)}$alkyl$C_{(3-4)}$cycloalkyl and -$C_{(1-5)}$alkyl are unsubstituted or substituted with one to six fluorine atoms; and

R^5 is H or F.

3. The compound of claims 1 or 2, or a pharmaceutically acceptable salt thereof, wherein:

R^5 is H.

4. The compound of any one of claims 1 to 3, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is -$C_{(1-4)}$alkyl or -$C_{(0-3)}$alkyl$C_{(3-5)}$cycloalkyl;

wherein the -$C_{(1-4)}$alkyl and the -$C_{(0-3)}$alkyl$C_{(3-5)}$cycloalkyl are unsubstituted or substituted with one to six fluorine atoms.

5. The compound of any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is -$C_{(1-3)}$alkyl or -$C_{(0-3)}$alkyl$C_{(3-5)}$cycloalkyl;

wherein the -$C_{(1-3)}$alkyl and the -$C_{(0-3)}$alkyl$C_{(3-5)}$cycloalkyl are unsubstituted or substituted with one to six fluorine atoms.

6. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein:

R^1 is -$C_{(1-3)}$alkyl, wherein the -$C_{(1-3)}$alkyl is unsubstituted or substituted with one to three fluorine atoms.


7. The compound of any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof, wherein:


R^1 is $C_{(0-3)}$alkyl$C_{(3-5)}$cycloalkyl, wherein the -$C_{(0-3)}$alkyl$C_{(3-5)}$cycloalkyl is unsubstituted or substituted with one to six fluorine atoms.


8. The compound of any one of claims 1 to 5 and 7, or a pharmaceutically acceptable salt thereof, wherein:


R^1 is $C_{(1-2)}$alkyl$C_{(3-5)}$cycloalkyl, wherein the -$C_{(1-2)}$alkyl$C_{(3-5)}$cycloalkyl is unsubstituted or substituted with one to three fluorine atoms.

9. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^1 is:



,



,


, or


.

10. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein R^1 is:

is:



11. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

R^2 is -$C_{(3-4)}$cycloalkyl.

12. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

R^2 is cyclopropyl.

13. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

R^3 is -$C_{(0)}$alkyl$C_{(5-6)}$cycloalkyl, wherein the -$C_{(0)}$alkyl$C_{(5-6)}$cycloalkyl is unsubstituted or substituted with one to five fluorine atoms.


14. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

R^3 is -$C_{(0)}$alkyl$C_{(5-6)}$cycloalkyl, wherein the -$C_{(0)}$alkyl$C_{(5-6)}$cycloalkyl is unsubstituted or substituted with one to three fluorine atoms.

15. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

R^3 is -$C_{(0)}$alkyl$C_{(6)}$cycloalkyl, wherein the -$C_{(0)}$alkyl$C_{(6)}$cycloalkyl is unsubstituted or substituted with one to two fluorine atoms.

16. The compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, wherein

R^3 is .

17. The compound of any one of claims 1 to 16, or a pharmaceutically acceptable salt thereof, wherein

R^4 is a 5- to 6-membered heteroaryl having 1 to 4 heteroatoms selected from N and O;

wherein the 5- to 6-membered heteroaryl is unsubstituted or substituted with one or two R^{4b} groups;


each R^{4b} group is independently selected from -$C_{(0-1)}$alkyl$C_{(3)}$cycloalkyl or -$C_{(1-3)}$alkyl,

wherein the -$C_{(0-1)}$alkyl$C_{(3)}$cycloalkyl and -$C_{(1-3)}$alkyl are unsubstituted or substituted with one to four fluorine atoms.

18. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein

R^4 is pyridinyl that is unsubstituted or substituted with $C_{(1-2)}$alkyl that is unsubstituted or substituted with one to three fluorine atoms.

19. The compound of any one of claims 1 to 18, or a pharmaceutically acceptable salt thereof,

wherein wherein R^4 is .

20. The compound of any one of claims 1 to 17, or a pharmaceutically acceptable salt thereof, wherein

R^4 is pyrazolyl, triazolyl, isoxazolyl, or oxadiazolyl that is unsubstituted or substituted with one or two R^{4b} groups,

each R^{4b} group is independently selected from -$C_{(0-1)}$alkyl$C_{(3)}$cycloalkyl or -$C_{(1-3)}$alkyl,

wherein the -$C_{(0-1)}$alkyl$C_{(3)}$cycloalkyl and -$C_{(1-3)}$alkyl are unsubstituted or substituted with one to four fluorine atoms.

21. The compound of any one of claims 1 to 17 and 20, or a pharmaceutically acceptable salt thereof, wherein

R^4 is pyrazolyl, triazolyl, isoxazolyl, or oxadiazolyl that is unsubstituted or substituted with one or two R^{4b} groups,

each R^{4b} group is independently selected from -$C_{(1)}$alkyl$C_{(3)}$cycloalkyl or -$C_{(1-3)}$alkyl, wherein the -$C_{(1)}$alkyl$C_{(3)}$cycloalkyl and -$C_{(1-3)}$alkyl are unsubstituted or substituted with one to three fluorine atoms.

22. The compound of any one of claims 1 to 17, 20 and 21, or a pharmaceutically acceptable salt thereof, wherein R^4 is pyrazolyl, triazolyl, isoxazolyl, or oxadiazolyl that is unsubstituted or substituted with one or two R^{4b} groups,

each R^{4b} group is independently -$C_{(1-3)}$alkyl, wherein the -$C_{(1-3)}$alkyl is unsubstituted or substituted with one to three fluorine atoms.

23. The compound of any one of claims 1 to 17 and 20 to 22, or a pharmaceutically acceptable salt thereof, wherein R^4 is 1*H*-pyrazolyl , 1*H*-1,2,3-triazolyl, 2*H*-1,2,3-triazolyl, 1*H*-1,2,4-triazolyl, isoxazole-4-yl, or 1,2,5-oxadiazolyl that is unsubstituted or substituted with one or two R^{4b} groups.


24. The compound of any one of claims 1 to 17 and 20 to 23, or a pharmaceutically acceptable salt thereof, wherein R^4 is 1*H*-pyrazolyl , 1*H*-1,2,3-triazolyl, 2*H*-1,2,3-triazolyl, 1*H*-1,2,4-triazolyl, isoxazole-4-yl, isoxazole-3-yl, or 1,2,5-oxadiazolyl that is unsubstituted or substituted with one or two R^{4b} groups.

25. The compound of any one of claims 1 to 17 and 20 to 23, or a pharmaceutically acceptable salt thereof, wherein R^4 is 1*H*-pyrazol-3-yl, 1*H*-pyrazol-4-yl, 1H-pyrazol-5-yl, 1*H*-1,2,3-triazol-5-yl, 2*H*-1,2,3-triazol-4-yl, 1*H*-1,2,4-triazol-5-yl, isoxazole-4-yl, or 1,2,5-oxadiazol-3-yl that is unsubstituted or substituted with one or two R^{4b} groups.


26. The compound of any one of claims 1 to 17 and 20 to 25, or a pharmaceutically acceptable salt thereof, wherein R^4 is 1*H*-pyrazol-3-yl, 1*H*-pyrazol-4-yl, 1H-pyrazol-5-yl, 1*H*-1,2,3-triazol-


5-yl, 2*H*-1,2,3-triazol-4-yl, 1*H*-1,2,4-triazol-5-yl, isoxazole-4-yl, isoxazole-3-yl or 1,2,5-oxadiazol-3-yl that is unsubstituted or substituted with one or two R^{4b} groups.

27. The compound of any one of claims 1 to 17 , 20 to 23 and 25 or a pharmaceutically acceptable salt thereof, wherein R^4 is:




28. The compound of any one of claims 1 to 17, and 20 to 26 or a pharmaceutically acceptable salt thereof, wherein R^4 is







29. The compound of any one of claims 1 to 17 or 20 to 28, or a pharmaceutically acceptable salt thereof, wherein R^4 is:




30. The compound of any one of claims 1 to 17 or 20 to 28, or a pharmaceutically acceptable salt thereof, wherein R^4 is:



31. The compound of any one of claims 1 to 17 or 20 to 28, or a pharmaceutically acceptable salt thereof, wherein R^4 is:



32. The compound of any one of claims 1 to 17 or 20 to 28, or a pharmaceutically acceptable salt thereof, wherein R^4 is:



or


33. The compound of any one of claims 1-16, or a pharmaceutically acceptable salt thereof, wherein:

R^4 is -$C_{(3)}$cycloalkyl;

wherein the $C_{(3)}$cycloalkyl is unsubstituted or substituted with one to three R^{4a} groups; and

each R^{4a} group is independently selected from -$C_{(1\text{-}2)}$alkyl that is unsubstituted or substituted with one to three fluorine atoms; and


wherein the compound of Formula **I** is a compound of Formula **Ia**:





Ia


34. The compound of any one of claims 1 to 33, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the compounds in Table 1A, Table 1AA and Table 1B.


35. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;












;



;



;



;



;



;

;

;

;

;

;

;

;

;

;



;



;



;



;



;



;


;



;



;



;





36. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;



;


























;


;


;


;


;


;


;


;


;


;


;



;



;



; and



.


37. The compound of claim 35 or 36, or a pharmaceutically acceptable salt thereof, wherein the compound is selected from


;


;



;


;




and .

38. The compound of claim 37, or a pharmaceutically acceptable salt thereof, which is




.

39. The compound of claim 37, or a pharmaceutically acceptable salt thereof, which is




.

40. The compound of claim 37, or a pharmaceutically acceptable salt thereof, which is




.

41. The compound of claim 37, or a pharmaceutically acceptable salt thereof, which is



42. The compound of claim 37, or a pharmaceutically acceptable salt thereof, which is



43. A pharmaceutical composition, comprising a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

44. A pharmaceutical composition made by mixing a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

45. The pharmaceutical composition of claim 43 or 44, which is administered orally.

46. The pharmaceutical composition of claim 45, which is administered as a tablet or a capsule.

47. A process for making a pharmaceutical composition comprising mixing a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

48. A method for treating and/or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease comprising administering to a subject in need thereof a therapeutically

effective amount of a compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof.

49. The method of claim 48, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is selected from the group consisting of: psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, hidradenitis suppurativa, bullous pemphigold, atopic dermatitis, vitiligo, multiple sclerosis, asthma, uveitis, chronic obstructive pulmonary disorder, multiple myeloma, and systemic lupus erythematosus.

50. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is psoriasis.

51. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is psoriatic arthritis.

52. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is rheumatoid arthritis.

53. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is ankylosing spondylitis.

54. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is hidradenitis suppurativa.

55. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is bullous pemphigold.

56. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is atopic dermatitis.

57. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is vitiligo.

58. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is multiple sclerosis.

59. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is systemic lupus erythematosus.

60. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is asthma.

61. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is uveitits.

62. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is chronic obstructive pulmonary disorder.

63. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is multiple myeloma.

64. The method of claim 49, wherein the IL-17A mediated inflammatory syndrome, disorder, or disease is systemic lupus erythematosus.

65. The method of any of claims 48 to 64, wherein the compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, is administered orally.

66. The method of any of claims 48 to 65, wherein the compound of any one of the preceding claims, or a pharmaceutically acceptable salt thereof, is administered as a tablet or a capsule.

67. A compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, for use in treating and/or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease.

68. A compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, for use in medical therapy.

69. The use of a compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, for treating and/or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease.

70. The use of a compound of any one of claims 1 to 42, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating and/or ameliorating an IL-17A mediated inflammatory syndrome, disorder, or disease.

71. A compound or method as described herein.